Improved Risk Stratification for Progression from Mild Cognitive Impairment to Alzheimer's Disease with a Multi-Analytical Evaluation of Amyloid-β Positron Emission Tomography.
暂无分享,去创建一个
J. Seibyl | K. Ishii | P. Cumming | P. Bartenstein | A. Rominger | M. Brendel | Kuangyu Shi | J. Sauerbeck | L. Beyer | I. Alberts | Franziska Scheiwein | Chisa Hosakawa | P. Bartenstein
[1] P. Malhotra,et al. Optimisation and usefulness of quantitative analysis of 18F-florbetapir PET. , 2019, The British journal of radiology.
[2] A. Chincarini,et al. Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC) , 2019, NeuroImage: Clinical.
[3] H. Struyfs,et al. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging , 2019, NeuroImage: Clinical.
[4] V. Grau,et al. Classification of amyloid PET images using novel features for early diagnosis of Alzheimer’s disease and mild cognitive impairment conversion , 2019, Nuclear medicine communications.
[5] Sterling C. Johnson,et al. Predicting Alzheimer’s disease progression using multi-modal deep learning approach , 2019, Scientific Reports.
[6] C. Jack,et al. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers , 2017, The Lancet Neurology.
[7] C. Jack,et al. Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework , 2017, Neurobiology of Aging.
[8] J. Seibyl,et al. Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[9] P. Pasqualetti,et al. Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study. , 2016, JAMA neurology.
[10] A. Villringer,et al. Feasibility and acceptance of simultaneous amyloid PET/MRI , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[11] S. Shokouhi,et al. Reference tissue normalization in longitudinal 18F-florbetapir positron emission tomography of late mild cognitive impairment , 2016, Alzheimer's Research & Therapy.
[12] Stefanie Schreiber,et al. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes. , 2015, JAMA neurology.
[13] I. Choo,et al. Structural MRI and Amyloid PET Imaging for Prediction of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment: A Meta-Analysis , 2015, Alzheimer's & Dementia.
[14] William J. Jagust,et al. Measurement of Longitudinal β-Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios , 2015, The Journal of Nuclear Medicine.
[15] Daniel Bandy,et al. Improved Power for Characterizing Longitudinal Amyloid-β PET Changes and Evaluating Amyloid-Modifying Treatments with a Cerebral White Matter Reference Region , 2015, The Journal of Nuclear Medicine.
[16] John Seibyl,et al. Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction , 2015, NeuroImage.
[17] Nick C Fox,et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.
[18] Keith A. Johnson,et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging , 2013, Alzheimer's & Dementia.
[19] Rik Ossenkoppele,et al. Longitudinal Amyloid Imaging Using 11C-PiB: Methodologic Considerations , 2013, The Journal of Nuclear Medicine.
[20] C. Bottino,et al. Correlation of brain structural and functional changes in amnestic mild cognitive impairment and mild Alzheimer's disease: A voxel-by-voxel analysis in a single cohort of patients in Brazil , 2013, Alzheimer's & Dementia.
[21] M. Viitanen,et al. [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[22] C. Jack,et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.
[23] M. Mintun,et al. Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline , 2013, Alzheimer disease and associated disorders.
[24] J. Schneider,et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.
[25] J O Rinne,et al. Amyloid PET imaging in patients with mild cognitive impairment , 2011, Neurology.
[26] R. Coleman,et al. Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.
[27] Nick C Fox,et al. Conversion of amyloid positive and negative MCI to AD over 3 years , 2009, Neurology.
[28] Nick C Fox,et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.
[29] Anders M. Dale,et al. Reliability in multi-site structural MRI studies: Effects of gradient non-linearity correction on phantom and human data , 2006, NeuroImage.
[30] Karl J. Friston,et al. Unified segmentation , 2005, NeuroImage.
[31] Alexander Hammers,et al. Three‐dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe , 2003, Human brain mapping.
[32] Alan C. Evans,et al. A nonparametric method for automatic correction of intensity nonuniformity in MRI data , 1998, IEEE Transactions on Medical Imaging.
[33] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[34] T. Werner,et al. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis. , 2019, Journal of Alzheimer's disease : JAD.
[35] C. Jack,et al. Framework : Towards a Biological Definition of Alzheimer ’ s Disease 1 2 draft 9-19-17 3 4 5 , 2017 .
[36] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.